Published in J Clin Invest on May 01, 1984
Metallic ions as therapeutic agents in tissue engineering scaffolds: an overview of their biological applications and strategies for new developments. J R Soc Interface (2011) 1.18
Medical applications and toxicities of gallium compounds. Int J Environ Res Public Health (2010) 1.15
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Gallium modulates osteoclastic bone resorption in vitro without affecting osteoblasts. Br J Pharmacol (2010) 0.87
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer (1997) 0.85
Medical management of hypercalcaemia. Br J Clin Pharmacol (1992) 0.84
Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes. Antioxid Redox Signal (2012) 0.84
Bone tissue incorporates in vitro gallium with a local structure similar to gallium-doped brushite. J Biol Inorg Chem (2003) 0.81
Distribution of trace levels of therapeutic gallium in bone as mapped by synchrotron x-ray microscopy. Proc Natl Acad Sci U S A (1990) 0.79
A Novel Glass Polyalkenoate Cement for Fixation and Stabilisation of the Ribcage, Post Sternotomy Surgery: An ex-Vivo Study. J Funct Biomater (2013) 0.77
Synthesis and characterization of cerium- and gallium-containing borate bioactive glass scaffolds for bone tissue engineering. J Mater Sci Mater Med (2015) 0.77
Ga(III) Nanoparticles Inhibit Growth of both Mycobacterium tuberculosis and HIV and Release of Interleukin-6 (IL-6) and IL-8 in Coinfected Macrophages. Antimicrob Agents Chemother (2017) 0.75
Effect of gallium nitrate on the expression of osteoprotegerin and receptor activator of nuclear factor‑κB ligand in osteoblasts in vivo and in vitro. Mol Med Rep (2015) 0.75
The determination of creatinine in plasma or serum, and in urine; a critical examination. Biochem J (1954) 4.92
Biochemical evaluation of patients with cancer-associated hypercalcemia: evidence for humoral and nonhumoral groups. N Engl J Med (1980) 3.15
Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol (1979) 1.95
Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer (1983) 1.03
Lymphokine-mediated bone resorption requires endogenous prostaglandin synthesis. J Exp Med (1981) 0.97
Clinical toxicologic and pharmacologic studies of gallium nitrate. Cancer (1979) 0.95
Inhibition of parathyroid hormone stimulated bone resorption in vitro by the antibiotic mithramycin. Calcif Tissue Res (1973) 0.87
Studies on the accumulation mechanisms of radioisotopes used in tumor diagnostic. Strahlentherapie (1971) 0.86
Administration of gallium nitrate by continuous infusion: lack of chronic nephrotoxicity confirmed by studies of enzymuria and beta 2-microglobulinuria. Cancer Treat Rep (1983) 0.85
Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell (1991) 9.40
Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med (1998) 6.83
Vitamin D and bisphosphonate response. Osteoporos Int (2014) 5.04
United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol (2001) 3.24
The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med (1992) 2.99
Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med (1990) 2.76
All-trans-retinoic acid: what is it good for? J Clin Oncol (1992) 2.03
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood (1997) 1.69
Induction of prostaglandin E synthesis in normal and neoplastic macrophages: role for colony-stimulating factor(s) distinct from effects on myeloid progenitor cell proliferation. Proc Natl Acad Sci U S A (1979) 1.63
Limitation of excessive myelopoiesis by the intrinsic modulation of macrophage-derived prostaglandin E. Science (1978) 1.60
Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A (2000) 1.57
Flavimonas oryzihabitans (CDC group Ve-2) bacteraemia associated with Hickman catheters. J Hosp Infect (1992) 1.56
Two cases of extramedullary acute promyelocytic leukemia. Cytogenetics, molecular biology, and phenotypic and clinical studies. Cancer (1994) 1.45
CD2 expression and PML/RAR-alpha transcripts in acute promyelocytic leukemia. Blood (1993) 1.41
Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol (1997) 1.34
Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res (1992) 1.26
Prostaglandin E2 induces receptive behaviors in female Xenopus laevis. Horm Behav (1985) 1.24
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood (2000) 1.23
Erythropoietin is both a mitogen and a survival factor. Blood (1991) 1.23
Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood (1998) 1.20
Accuracy of paramedic identification of stroke and transient ischemic attack in the field. Prehosp Emerg Care (1998) 1.19
Prostaglandins and cancer: a review of tumor initiation through tumor metastasis. Prostaglandins (1981) 1.18
Prostaglandin E inhibition of T-lymphocyte colony formation: a possible mechanism of monocyte modulation of clonal expansion. J Clin Invest (1979) 1.18
Methylglyoxal-bis(guanylhydrazone) (Methyl-GAG): current status and future prospects. J Clin Oncol (1983) 1.07
Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med (1988) 1.07
The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int (2012) 1.05
Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol (1986) 1.05
Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood (1993) 1.04
Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion. Cancer (1983) 1.03
Prostaglandin production by human blood monocytes and mouse peritoneal macrophages: synthesis dependent on in vitro culture conditions. Prostaglandins (1981) 1.01
Comparison of commercially available parathyroid hormone immunoassays in the differential diagnosis of hypercalcemia due to primary hyperparathyroidism or malignancy. Ann Intern Med (1979) 1.01
Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in renal failure. Am J Med (1979) 0.99
Prognostic significance of minimal residual disease detection and PML/RAR-alpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood (2001) 0.98
Bone strength and related traits in HcB/Dem recombinant congenic mice. J Bone Miner Res (2001) 0.97
Lymphokine-mediated bone resorption requires endogenous prostaglandin synthesis. J Exp Med (1981) 0.97
Carboplatin-based chemotherapy with pharmacokinetic analysis for patients with hemodialysis-dependent renal insufficiency. Cancer Chemother Pharmacol (1990) 0.97
Chemotherapy of metastatic sweat gland carcinoma. A retrospective review. Am J Clin Oncol (1985) 0.96
Renal function after pituitary ablation for diabetic retinopathy. JAMA (1969) 0.95
Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A (1992) 0.94
Effects of heat shock, stannous chloride, and gallium nitrate on the rat inflammatory response. Cell Stress Chaperones (2001) 0.94
Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol (2000) 0.94
Increased prostaglandin synthesis by macrophages from tumor-bearing mice. J Immunol (1979) 0.94
All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Intern Med (1994) 0.93
Immunoblastic lymphadenopathy with hypercalcemia. Mt Sinai J Med (1980) 0.91
Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol (1994) 0.91
Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst (1993) 0.91
Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res (1995) 0.90
Prostaglandin E1 inhibits collagenase gene expression in rabbit synoviocytes and human fibroblasts. Endocrinology (1992) 0.89
Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. Blood (1995) 0.88
Homonuclear indor spectroscopy as a means of simplifying and analyzing proton magnetic resonance spectra of peptides and as a basis for determining secondary and tertiary conformations of complex peptides. Biochemistry (1972) 0.88
Microdistribution of lead in bone: a new approach. Neurotoxicology (1992) 0.88
Tumor necrosis factor-alpha stimulates phosphatidylinositol breakdown by phospholipase C to coordinately increase the levels of diacylglycerol, free arachidonic acid and prostaglandins in an osteoblast (MC3T3-E1) cell line. Biochim Biophys Acta (1991) 0.87
Gallium increases bone calcium and crystallite perfection of hydroxyapatite. Calcif Tissue Int (1986) 0.87
Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia. J Clin Oncol (1985) 0.87
Physiological and pharmacological effects of zinc on immune response. Ann N Y Acad Sci (1990) 0.87
Clinical evaluation of succinylated Acinetobacter glutaminase-asparaginase in adult leukemia. Cancer Treat Rep (1982) 0.87
Elevated plasma lipid peroxide content correlates with rapid plasma clearance of all-trans-retinoic acid in patients with advanced cancer. Cancer Res (1994) 0.86
Clinical pharmacology of all-trans retinoic acid. Leukemia (1994) 0.86
Administration of gallium nitrate by continuous infusion: lack of chronic nephrotoxicity confirmed by studies of enzymuria and beta 2-microglobulinuria. Cancer Treat Rep (1983) 0.85
Stage-dependent reduction in T colony formation in Hodgkin's disease. Coincidence with monocyte synthesis of prostaglandins. J Clin Invest (1980) 0.85
Effect of gallium on bone mineral properties. Calcif Tissue Int (1988) 0.85
Novel retinoic acid receptor-alpha transcripts in acute promyelocytic leukemia responsive to all-trans-retinoic acid. J Natl Cancer Inst (1990) 0.85
Studies on the proteolytic activity of gamma-globulin preparations. Biochem J (1967) 0.85
Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin Cancer Res (1996) 0.84
A review of clinical trials of therapies for osteoporosis using fracture as an end point. J Clin Densitom (1999) 0.84
A review of calcium preparations. Nutr Rev (1994) 0.84
Dopamine administration in oliguria and oliguric renal failure. Crit Care Med (1981) 0.84
Hypercalcaemia and increased serum interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma. Br J Haematol (1995) 0.84
Plasmodesmata-located protein overexpression negatively impacts the manifestation of systemic acquired resistance and the long-distance movement of Defective in Induced Resistance1 in Arabidopsis. Plant Biol (Stuttg) (2014) 0.84
Acute promyelocytic leukemia cell line AP-1060 established as a cytokine-dependent culture from a patient clinically resistant to all-trans retinoic acid and arsenic trioxide. Leukemia (2004) 0.83
Hodgkin's disease presenting with rectal symptoms in a homosexual male. A case report and review of the literature. Cancer Invest (1984) 0.83
Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis. Cancer Res (1986) 0.83
Phase II study of etoposide in the treatment of esophageal carcinoma. Cancer Treat Rep (1983) 0.83
Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Cancer Treat Rep (1983) 0.82
The importance of the etiology of hypokalemic alkalosis in determining replacement therapy. Metabolism (1965) 0.82
Asymptomatic impacted mandibular third molar in the subcondylar-sigmoid notch region associated with extensive sclerotic bone. J Oral Med (1985) 0.82
Inhaled aerosolization of all-trans-retinoic acid for targeted pulmonary delivery. Cancer Chemother Pharmacol (2000) 0.82
Maintenance etidronate in the prevention of malignancy-associated hypercalcemia. Arch Intern Med (1987) 0.82
Clinical pharmacology of all-trans retinoic acid. Leukemia (1994) 0.81
Protein kinases A and C positively regulate G protein-dependent activation of phosphatidylinositol-specific phospholipase C by tumor necrosis factor-alpha in MC3T3-E1 osteoblasts. J Cell Biochem (1997) 0.81
Arsenicals in hematologic cancers. Semin Oncol (2000) 0.81
Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol (1993) 0.81
Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases. J Clin Oncol (1987) 0.80
Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer (1991) 0.80
Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol (1999) 0.80
Distribution of trace levels of therapeutic gallium in bone as mapped by synchrotron x-ray microscopy. Proc Natl Acad Sci U S A (1990) 0.79
Metabolic effects of gallium nitrate administered by prolonged infusion. Cancer Treat Rep (1985) 0.79